Farxiga has been granted Fast Track status by the FDA
Fast Track designation has been granted to Farxiga to prevent heart and kidney failure in patients with chronic kidney disease.
List view / Grid view
Fast Track designation has been granted to Farxiga to prevent heart and kidney failure in patients with chronic kidney disease.
A clinical trial to study a chronic obstructive pulmonary disease treatment has found that the drug is effective and safe.
The government in China has stated that small quantities of generic medicines that are legal in foreign countries will no longer be classed as “fake drugs”.
Young children in Spain have developed hypertrichosis, also known as ‘werewolf syndrome’, after a reflux drug was contaminated with an alopecia treatment.
NICE and GW Pharma will work together to address the issues highlighted in its evaluation of cannabidiol for treating two types of epilepsy.
The licence extension submission for Invokana and Vokanamet has been accepted by the EMA.
A large number of drug manufacturers are failing to complete the FDA's Accelerated Approval Program, meaning not all available drugs are fully approved, finds a study.
The pharmaceutical company is planning to appeal the decision to pay the state for damages relating to the US opioid crisis.
Five pharma companies have filed a complaint in Canadian court over new rules intended to lower the price of drugs in the country.
Around half of HRT products have been reported as out of stock in UK pharmacies due to supply issues in China, leading to a shortage.
A recent report has predicted that the cervical cancer vaccine market will increase to $6bn by the end of the forecast period.
According to new research, innovation in drug delivery is accelerating in Europe, with Switzerland as Europe’s biggest drug delivery innovator.
Sir Andrew Dillion will be stepping down from his role as chief executive of NICE next year, after holding his position for 20 years.
The two pharmaceutical companies are facing a legal battle after Mylan filed a new drug application for a generic of Novo Nordisk’s Victoza.
XTANDI® sNDA seeks to add an indication for men with prostate cancer that's spread but is sensitive to hormone therapy.